Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Economy
Sanofi to refocus R&D, cut jobs in France and Germany
by Michael McCoy
June 21, 2019
| A version of this story appeared in
Volume 97, Issue 25
Sanofi plans to reduce its R&D staff of about 10,000 by 466 positions in France and Germany as part of a program to sharpen its research focus. Sanofi’s research priorities will be oncology, immunology, rare diseases, and vaccines. The French drugmaker says it will end new R&D in cardiovascular therapy, continuing only current programs. In diabetes research it will focus on treatments that address the underlying causes of the disease.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter